William Blair Estimates ImageneBio FY2025 Earnings

ImageneBio, Inc. (NASDAQ:IMA) – Stock analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for shares of ImageneBio in a report issued on Wednesday, November 12th. William Blair analyst M. Phipps forecasts that the company will earn ($9.34) per share for the year. The consensus estimate for ImageneBio’s current full-year earnings is ($0.91) per share. William Blair also issued estimates for ImageneBio’s Q4 2025 earnings at ($1.15) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.38) EPS, FY2027 earnings at ($4.12) EPS, FY2028 earnings at ($4.16) EPS and FY2029 earnings at ($3.52) EPS.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($1.44).

Several other research firms also recently commented on IMA. Wall Street Zen downgraded shares of ImageneBio from a “hold” rating to a “strong sell” rating in a research report on Saturday. Zacks Research cut shares of ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Wedbush cut their target price on shares of ImageneBio from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Leerink Partners initiated coverage on ImageneBio in a report on Friday, October 24th. They set an “outperform” rating and a $30.00 target price for the company. Finally, Weiss Ratings started coverage on ImageneBio in a research report on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ImageneBio has an average rating of “Hold” and a consensus target price of $26.50.

ImageneBio Stock Down 2.0%

Shares of NASDAQ IMA opened at $8.16 on Monday. ImageneBio has a 12-month low of $7.24 and a 12-month high of $23.28. The firm has a market cap of $32.72 million, a PE ratio of -1.01 and a beta of 0.42. The company’s fifty day simple moving average is $8.26 and its 200 day simple moving average is $12.66.

Hedge Funds Weigh In On ImageneBio

Several institutional investors have recently bought and sold shares of the company. Deep Track Capital LP purchased a new position in ImageneBio in the third quarter worth $7,160,000. Bridgeway Capital Management LLC acquired a new position in shares of ImageneBio in the third quarter valued at approximately $104,000. Squarepoint Ops LLC acquired a new stake in shares of ImageneBio during the third quarter worth $197,000. Atlas Venture Life Science Advisors LLC purchased a new position in shares of ImageneBio during the 3rd quarter worth about $3,079,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of ImageneBio during the 3rd quarter valued at $4,409,000. 75.00% of the stock is owned by institutional investors and hedge funds.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.